Please read

$Orphazyme AS(ORPH.US)$
It's funny how people are buying stocks, dreaming that positive things would happen without DD. The clinical trials data were bad to begin with... it's no surprise that FDA would not approve the drug. The drug failed to meet primary and key secondary goals in phase 3 clinical trials. Meaning... there's no evidence at all showing that the drug is effective.

Hodl? to the moon? it's ok long term? FY'21 operating losses will increase 6 times, cash position expected at only 8 million USD by end of the year.

Do you DD and think hard before Pre market opens. Good luck

*New* For people who are saying buy the dip and the company just have to submit more evidence to FDA... do you even know what that means. It means the company has to conduct clinical trials again, it's not like your paper work incomplete just re-submit only...